Physician profile
Natalie C Light
NPI 1578565354
$2,572.17
in general payments reported to CMS, 2019-2025
34 companies · $409 in 2025
The $409 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $170 · 2021: $156 · 2022: $549 · 2023: $544 · 2024: $271 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.56 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $337.71 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $246.78 | 2019-2025 | Slynd |
| Pfizer INC. | $183.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $173.25 | 2019-2020 | |
| Abbvie INC. | $172.37 | 2019-2023 | |
| Organon LLC | $169.32 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $162.13 | 2021-2025 | |
| Gynesonics, INC. | $135.69 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $113.66 | 2022-2025 | Femring, Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $83.81 | 2020-2025 | |
| Vertical Pharmaceuticals, LLC | $80.37 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $76.55 | 2023-2025 | Myfembree |
| Amgen INC. | $74.01 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $67.31 | 2023 | |
| Amag Pharmaceuticals, INC. | $65.48 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $39.02 | 2023-2025 | Accrufer |
| Avion Pharmaceuticals | $34.61 | 2019-2022 | |
| Channel Medsystems, INC. | $33.05 | 2023 | |
| Therapeuticsmd, INC. | $32.59 | 2019-2022 | |
| Coopersurgical, INC. | $31.33 | 2022-2025 | |
| Exact Sciences Corporation | $30.75 | 2025 | Cologuard Collection Kit |
| Lupin INC. | $28.02 | 2019 | |
| Innovation Technologies INC | $24.37 | 2023 | Irrisept |
| Agile Therapeutics, INC. | $24.25 | 2021 | |
| Minerva Surgical, INC | $22.79 | 2022 | |
| Integra Lifesciences Corporation | $21.20 | 2025 | Cusa Clarity, Codman Hakim, Codman Certas |
| Hologic Sales and Service, LLC | $20.23 | 2025 | Omni Hysteroscope, Novasure, Myosure Tissue Removal Device |
| Cumberland Pharmaceuticals, INC. | $16.59 | 2022 | |
| Evofem Biosciences, INC. | $16.24 | 2021 | |
| Myovant Sciences INC. | $15.15 | 2022 | |
| Sage Therapeutics, LLC | $13.80 | 2025 | Zurzuvae |
| Pacira Pharmaceuticals Incorporated | $13.31 | 2020 | |
| Duchesnay USA Incorporated | $13.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.